Neomycin (topical): Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Kiran Singh moved page Neomycin to Neomycin (topical) without leaving a redirect)
 
(11 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag=<!--Overview-->
|authorTag={{DB}}
|aOrAn=a
|genericName=Neomycin
|hasBlackBoxWarning=Yes
|aOrAn=an
|adverseReactions=<!--Black Box Warning-->
|drugClass=anti- bacterial agent, anti- infective agent
|indicationType=treatment
|indication=[[hepatic encephalopathy]], preoperative preparation of bowel for procedure, prophylaxis for infection of skin,in minor cuts, scrapes, and burns
|adverseReactions=[[diarrhea]], [[nausea]], [[vomiting]]
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
Line 16: Line 19:
* Dosing Information
* Dosing Information


:* Dosage
:* 4 to 12 g/day ORALLY in divided doses for 5 to 6 days, maximum 12 g/day; do not use longer than 2 wks.


=====Infection of skin, In minor cuts, scrapes, and burns; Prophylaxis=====
=====Infection of skin, In minor cuts, scrapes, and burns; Prophylaxis=====
Line 22: Line 25:
* Dosing Information
* Dosing Information


:* Dosage
:* Apply small amount TOPICALLY to affected area not more than 2 to 3 times daily; may be covered with a sterile bandage.


=====Preparation of bowel for procedure, Preoperative; Adjunct=====
=====Preparation of bowel for procedure, Preoperative; Adjunct=====
Line 28: Line 31:
* Dosing Information
* Dosing Information


:* Dosage
:* 1 g ORALLY 19, 18, and 9 hrs prior to surgery in combination with recommended bowel preparation regimen which includes erythromycin.


<!--Off-Label Use and Dosage (Adult)-->
<!--Off-Label Use and Dosage (Adult)-->


<!--Guideline-Supported Use (Adult)-->
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
|offLabelAdultGuideSupport=* There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
|offLabelAdultNoGuideSupport=* There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Pediatric Indications and Dosage-->
<!--Pediatric Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
|fdaLIADPed======Infection of skin, In minor cuts, scrapes, and burns; Prophylaxis=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.


<!--Off-Label Use and Dosage (Pediatric)-->
<!--Off-Label Use and Dosage (Pediatric)-->


<!--Guideline-Supported Use (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
|offLabelPedGuideSupport=* There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
|offLabelPedNoGuideSupport=* There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->
|contraindications=* Condition1
|contraindications=<!--Warnings-->
 
|warnings=*Warnings: For external use only.  Do not use: if you are allergic to any of the ingredients, in the eyes, over large areas of the body.  Ask a doctor before use if you have: large puncture wounds, animal bites, serious burns.
<!--Warnings-->
|warnings=* Description


====Precautions====
*Stop use and ask a doctor if: you need to use longer than one week, condition persists or gets worse, symptoms persist for more than one week or clear up and occur again within a few days, rash or other allergic reaction develops.


* Description
* Keep out of reach of children.  If swallowed, get medical help or contact a Poison Control Center right away.


<!--Adverse Reactions-->
<!--Adverse Reactions-->


<!--Clinical Trials Experience-->
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|drugInteractions=<!--Use in Specific Populations-->
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
 
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''


There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
* There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
Line 258: Line 81:


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
|administration=* Oral
|administration=* Adults and children over 2 years of age or older: Clean the affected area.  Apply contents of packet to surface of affected area 2 times daily.  Gently rub in. Children under 2 years of age: Ask a doctor.
 
* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.


<!--Overdosage-->
<!--Overdosage-->
|overdose====Acute Overdose===
|drugBox=[[File:Neomycin wiki.png|600px|thumbnail|left]]
 
{{clear}}
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|mechAction=*  
|mechAction=*  


Line 308: Line 108:
<!--How Supplied-->
<!--How Supplied-->
|howSupplied=*
|howSupplied=*
|packLabel=<!--Patient Counseling Information-->
|packLabel=[[File:Neomycin pdp.jpg|600px|thumbnail|left]]
{{clear}}
 
[[File:Neomycin label.png|600px|thumbnail|left]]
{{clear}}
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


Line 315: Line 119:


<!--Brand Names-->
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title =  | url =  }}</ref>
|brandNames=Neo-Fradin


<!--Look-Alike Drug Names-->
<!--Look-Alike Drug Names-->

Latest revision as of 19:33, 18 May 2015

Neomycin (topical)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Deepika Beereddy, MBBS [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Neomycin (topical) is an anti- bacterial agent, anti- infective agent that is FDA approved for the treatment of hepatic encephalopathy, preoperative preparation of bowel for procedure, prophylaxis for infection of skin,in minor cuts, scrapes, and burns. Common adverse reactions include diarrhea, nausea, vomiting.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Hepatic encephalopathy
  • Dosing Information
  • 4 to 12 g/day ORALLY in divided doses for 5 to 6 days, maximum 12 g/day; do not use longer than 2 wks.
Infection of skin, In minor cuts, scrapes, and burns; Prophylaxis
  • Dosing Information
  • Apply small amount TOPICALLY to affected area not more than 2 to 3 times daily; may be covered with a sterile bandage.
Preparation of bowel for procedure, Preoperative; Adjunct
  • Dosing Information
  • 1 g ORALLY 19, 18, and 9 hrs prior to surgery in combination with recommended bowel preparation regimen which includes erythromycin.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

  • There is limited information regarding Off-Label Guideline-Supported Use of Neomycin (topical) in adult patients.

Non–Guideline-Supported Use

  • There is limited information regarding Off-Label Non–Guideline-Supported Use of Neomycin (topical) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Infection of skin, In minor cuts, scrapes, and burns; Prophylaxis

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

  • There is limited information regarding Off-Label Guideline-Supported Use of Neomycin (topical) in pediatric patients.

Non–Guideline-Supported Use

  • There is limited information regarding Off-Label Non–Guideline-Supported Use of Neomycin (topical) in pediatric patients.

Contraindications

There is limited information regarding Neomycin (topical) Contraindications in the drug label.

Warnings

  • Warnings: For external use only. Do not use: if you are allergic to any of the ingredients, in the eyes, over large areas of the body. Ask a doctor before use if you have: large puncture wounds, animal bites, serious burns.
  • Stop use and ask a doctor if: you need to use longer than one week, condition persists or gets worse, symptoms persist for more than one week or clear up and occur again within a few days, rash or other allergic reaction develops.
  • Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Neomycin (topical) Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Neomycin (topical) Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Neomycin (topical) Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Neomycin (topical) in women who are pregnant.
Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category
  • There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Neomycin (topical) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Neomycin (topical) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Neomycin (topical) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Neomycin (topical) with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Neomycin (topical) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Neomycin (topical) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Neomycin (topical) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Neomycin (topical) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Neomycin (topical) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Neomycin (topical) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Neomycin (topical) in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Adults and children over 2 years of age or older: Clean the affected area. Apply contents of packet to surface of affected area 2 times daily. Gently rub in. Children under 2 years of age: Ask a doctor.

Monitoring

There is limited information regarding Neomycin (topical) Monitoring in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Neomycin (topical) in the drug label.

Overdosage

There is limited information regarding Neomycin (topical) overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

Mechanism of Action

Structure

File:Neomycin (topical)01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Neomycin (topical) in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Neomycin (topical) in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Neomycin (topical) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Neomycin (topical) in the drug label.

How Supplied

Storage

There is limited information regarding Neomycin (topical) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Neomycin (topical) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Neomycin (topical) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Neomycin (topical) in the drug label.

Precautions with Alcohol

  • Alcohol-Neomycin (topical) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Neo-Fradin

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject: 

 |Page Name=Neomycin (topical)
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Neomycin (topical)
 |Label Name=Neomycin (topical)11.png

}}

{{#subobject: 

 |Label Page=Neomycin (topical)
 |Label Name=Neomycin (topical)11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Neomycin_(topical)&oldid=1099221"